December 4, 2020 — Adjuvant nivolumab demonstrated clinically meaningful improvements in relapse-free survival, overall survival, and distant metastasis-free survival vs placebo in patients with high-risk resected melanoma, even after accounting for disease stage and post-recurrence survival, supporting the use of the anti–PD-1 antibody as a standard adjuvant therapy.
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses the treatment of lactate dehydrogenase (LDH)–high melanoma.
Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.
Joshua K. Sabari, MD, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer.
Jeffrey S. Weber, MD, PhD, discusses emerging therapies in melanoma.
In our exclusive interview, Marc J. Braunstein, MD, PhD, provides perspective on data in the upfront and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.
Vamsidhar Velcheti, MD, discusses the current and emerging treatment options for patients with ALK- and ROS1-positive non–small cell lung cancer.
Elaine Shum, MD, discusses consulting patients with non-small cell lung cancer on the use of osimertinib.
Shella Saint Fleur-Lominy, MD, PhD, discusses targeted pathways in myeloproliferative neoplasms.
Mohammad Maher Abdul-Hay, MD, discusses the use of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) to guide transplant eligibility in acute lymphoblastic leukemia (ALL).
Diane M. Simeone, MD, discusses the importance of germline testing in pancreatic cancer.
Aaron E. Katz, MD, FACS, discusses re-classifying low-risk prostate scores with the 17-gene Oncotype DX Genomic Prostate Score.
Aaron E. Katz, MD, FACS, discusses strategies for determining low-risk prostate cancer.
Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.
Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.
Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.
Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.
Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.
Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.
Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Diane M. Simeone, MD, discusses the benefit of using a gemcitabine “sandwich approach” in patients with resectable pancreatic cancer.
Anna C. Pavlick, DO, discusses updated results from the COLUMBUS trial in metastatic melanoma.
Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.
Bhavana Pothuri, MD, discusses the importance of obtaining patient-reported outcomes in ovarian cancer.
Faith E. Davies, MD, discusses the research being done in patients with multiple myeloma who are refractory to lenalidomide.
Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.
Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.
Mohammad Maher Abdul-Hay, MD, discusses the future of targeted therapy in acute lymphoblastic leukemia.
Faith E. Davies, MD, discusses the dosing of carfilzomib in the treatment of patients with multiple myeloma.
Gareth J. Morgan, MD, PhD, discusses the role of venetoclax in treating patients with multiple myeloma.
